Lotte B. Knudsen

Specialty: GLP-1 Drug Development

Location: Unknown

Tier: ELITE

H-Index: 138

Years Active: 0

Hospital Affiliations

• Novo Nordisk - Faculty

Key Publications

1. "Semaglutide lowers body weight in rodents via distributed neural pathways." - JCI Insight (2020)
2. "Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide." - J Med Chem (2015)
3. "The Discovery and Development of Liraglutide and Semaglutide." - Front Endocrinol (Lausanne) (2019)
4. "Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist." - Sci Transl Med (2018)
5. "The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE(-/-) and LDLr(-/-) Mice by a Mechanism That Includes Inflammatory Pathways." - JACC Basic Transl Sci (2018)

Knowledge Graph Relationships

Lotte B. Knudsen is a GLP-1 Drug Development specialist affiliated with Novo Nordisk. Authored 5 scholarly articles.